Eagle Pharmaceuticals
50 Tice Blvd, Suite 315
Woodcliffe Lake
New Jersey
07677
United States
Tel: (201) 326-5300
Website: https://www.eagleus.com/
243 articles with Eagle Pharmaceuticals
-
Eagle Pharmaceuticals To Hold Conference Call At 8:30 A.M. EST Today To Discuss Licensing Agreement With Teva Pharmaceutical Industries To Commercialize Eagle’s Rapid Infusion Bendamustine
2/17/2015
-
Eagle Pharmaceuticals Announces Change In Fiscal Year End
1/20/2015
-
Eagle Pharmaceuticals Reports Fourth Quarter And Year End 2014 Financial Results
12/17/2014
-
Eagle Pharmaceuticals To Discuss 2014 Fourth Quarter And Year-End Financial Results On December 17, 2014
12/5/2014
-
Eagle Pharmaceuticals To Present At Piper Jaffray 2014 Healthcare Conference
11/20/2014
-
Eagle Pharmaceuticals Reports Positive Outcomes From Clinical Trial Of Bendamustine HCl Product Delivered Via Low-Volume, Rapidly Infused Admixture
11/10/2014
-
Eagle Pharmaceuticals To Present At Stifel 2014 Healthcare Conference
11/7/2014
-
Eagle Pharmaceuticals To Present At 21st Annual NewsMakers In The Biotechnology Industry Investment Conference
9/23/2014
-
Eagle Pharmaceuticals Announces That Teva Pharmaceutical Industries Limited Requests A Motion To Dismiss With Prejudice In Its Bendamustine Patent Infringement Lawsuit
9/17/2014
-
Eagle Pharmaceuticals Reports Third Quarter 2014 Results
8/11/2014
-
Eagle Pharmaceuticals Schedules Third Quarter Earnings Release And Conference Call
7/30/2014
-
FDA Approves Eagle Pharmaceuticals' Ryanodex® For The Treatment Of Malignant Hyperthermia
7/23/2014
-
Eagle PharmaceuticalsReceives Orphan Drug Designation For Lower Volume, Shorter Infusion Time Bendamustine Hydrochloride Product For Chronic Lymphocytic Leukemia And Indolent B-Cell Non-Hodgkin’s Lymphoma
7/8/2014
-
Eagle Pharmaceuticals Receives Tentative Approval For Patented, Ready-to-Dilute Bendamustine Hydrochloride Injection NDA
7/2/2014
-
Eagle Pharmaceuticals To Present At Jefferies and Co. 2014 Global Healthcare Conference
5/22/2014
-
Eagle Pharmaceuticals Reports Second Quarter 2014 Results
5/14/2014
-
Eagle Pharmaceuticals Schedules Second Quarter Earning Release And Conference Call
5/1/2014
-
Eagle Pharmaceuticals To Present At 39th Annual Deutsche Bank Health Care Conference
4/29/2014
-
Eagle Pharmaceuticals’ Exclusive Licensor Granted U.S. Patent For Dantrolene In The Treatment Of Heat Stroke
4/1/2014
-
NDA For Eagle Pharmaceuticals' Orphan Drug Ryanodex® For The Treatment Of Malignant Hyperthermia Accepted By FDA, Priority Review Granted
3/20/2014